Abstract:In recent years, adeno-associated virus (AAV) has become the most important vector for central nervous system (CNS) gene therapy. AAV has already shown promising results in the clinic, for several CNS diseases that cannot be treated with drugs, including neurodegenerative diseases, neuromuscular diseases, and lysosomal storage disorders. Currently, three of the four commercially available AAV-based drugs focus on neurological disorders, including Upstaza for aromatic l-amino acid decarboxylase deficiency, Luxturna for hereditary retinal dystrophy, and Zolgensma for spinal muscular atrophy. All these studies have provided paradigms for AAV-based therapeutic intervention platforms. AAV gene therapy, with its dual promise of targeting disease etiology and enabling 'long-term correction' of disease processes, has the advantages of immune privilege, high delivery efficiency, tissue specificity, and cell tropism in the CNS. Although AAV-based gene therapy has been shown to be effective in most CNS clinical trials, limitations have been observed in its clinical applications, which are often associated with side effects. In this review, we summarized the therapeutic progress, challenges, limitations, and solutions for AAV-based gene therapy in 14 types of CNS diseases. We focused on viral vector technologies, delivery routes, immunosuppression, and other relevant clinical factors. We also attempted to integrate several hurdles faced in clinical and preclinical studies with their solutions, to seek the best path forward for the application of AAV-based gene therapy in the context of CNS diseases. We hope that these thoughtful recommendations will contribute to the efficient translation of preclinical studies and wide application of clinical trials.

Adeno-Associated Viral Vectors in the Treatment of Epilepsy

Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures

AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges

AAV-based in vivo gene therapy for neurological disorders

Adeno‐associated Virus Vectors for Gene Therapy—focusing on Melanoma

Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

Various AAV Serotypes and Their Applications in Gene Therapy: An Overview

Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Adeno-associated virus therapies: Pioneering solutions for human genetic diseases

Adeno-Associated Virus-mediated Gene Therapy for Cardiac Tachyarrhythmia: A Systematic Review and Meta-analysis

Recombinant Adeno-Associated Virus Vectors for Gene Therapy of the Central Nervous System: Delivery Routes and Clinical Aspects

Unlocking the potential of adeno-associated virus in neuroscience: a brief review

Adeno-associated virus as a delivery vector for gene therapy of human diseases

A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases

Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

The clinical landscape for AAV gene therapies

A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsy

Adeno-Associated Virus (AAV) as a Vector for Gene Therapy

Adeno-associated virus vector as a platform for gene therapy delivery